Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 1, 1998, Pages 271-276

  Fahey, Jeanne M ^a   Pritchard, Gary A ^a   Von Moltke, Lisa L ^a   Pratt, John S ^a   Grassi, Jeffrey M ^a   Shader, Richard I ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE RECEPTOR; BUSPIRONE; DIZOCILPINE; DRUG METABOLITE; FLUMAZENIL; FLUNITRAZEPAM; ITRACONAZOLE; KETOCONAZOLE; PAROXETINE; TRIAZOLAM;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TRANSFORMATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; BINDING SITES; BIOTRANSFORMATION; FLUNITRAZEPAM; GABA MODULATORS; KETOCONAZOLE; MALE; MICE; RECEPTORS, GABA-A; TRIAZOLAM;

EID: 0031957091     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
2. Como JA and Dismukes WE (1994) Oral azole drugs as systemic antifungal theraphy. N Engl J Med 330:263-272.
3. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF and Benet LZ (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19.
4. Halpert JR (1995) Structural basis of selective cytochrome P450 inhibition. Annu Rev Pharmacol Toxicol 35:29-53.
5. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC and Cantilena LR (1993) Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. J Am Med Assoc 269:1513-1518.
6. Kauffman CA and Carver PL (1997) Antifungal agents in the 1990s. Current status and future developments. Drugs 53:539-544.
7. Kronbach T, Mathys D, Umeno M, Gonzalez FJ and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
8. Lopez F, Miller LG, Greenblatt DJ, Paul SM and Shader RI (1988) Low-dose alprazolam augments motor activity in mice. Pharmacol Biochem Behav 30:511-513
9. Miller LG, Greenblatt DJ, Barnhill JG and Shader RI (1988) Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased γ-aminobutyric acidA receptor function. J Pharmacol Exp Ther 246:170-176.
10. Newton DJ, Wang RW and Lu YH (1995) Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
11. Nielson M and Braestrup C (1980) Ethyl beta-carboline-3-carboxylate shows differential benzodiazepine receptor interaction. Nature (Lond) 286:606-607-
12. Olkkola KT, Backman JT and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther 55:481-485.
13. Schmider J, Greenblatt DJ, von Moltke LL and Shader RI (1996) Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacot 16:267-272.
14. Squires RF, Benson DI, Braestrup C, Coupet J, Klepner CA, Myers V and Beer B (1979) Some properties of brain specific benzodiazepine receptors: New evidence for multiple receptors. Pharmacol Biochem Behav 10:825-830.
15. Varhe A, Olkkola KT and Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56:601-607.
16. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS and Shader RI (1994) Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38: 23-31.
17. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
18. von Moltke LL, Greenblatt DJ, Harmatz JS and Shader RI (1993) Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47:268-276.
19. Wright CE, Greenblatt DJ, von Moltke LL, Ehrenberg BL, Harmatz JS, Corbett K and Shader RI (1997) Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences. Clin Pharmacol Ther 61:183.